NO20092743L - Antistoffer mot CD200R - Google Patents
Antistoffer mot CD200RInfo
- Publication number
- NO20092743L NO20092743L NO20092743A NO20092743A NO20092743L NO 20092743 L NO20092743 L NO 20092743L NO 20092743 A NO20092743 A NO 20092743A NO 20092743 A NO20092743 A NO 20092743A NO 20092743 L NO20092743 L NO 20092743L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- cd200r
- relates
- human inhibitory
- inhibitory cd200r
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Den foreliggende oppfinnelse vedrører bindende forbindelser som er spesifikke for den humane inhiberende CD200R, og anvendelser derav. Nærmere bestemt vedrører oppfinnelsen antistoffer som gjenkjenner den humane inhiberende CD200R og modulerer dens aktivitet ved inflammatoriske forstyrrelser og autoimmunforstyrrelser.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87661806P | 2006-12-22 | 2006-12-22 | |
PCT/US2007/026202 WO2008079352A2 (en) | 2006-12-22 | 2007-12-20 | Antibodies to cd200r |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20092743L true NO20092743L (no) | 2009-09-21 |
Family
ID=39563108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20092743A NO20092743L (no) | 2006-12-22 | 2009-07-21 | Antistoffer mot CD200R |
Country Status (14)
Country | Link |
---|---|
US (1) | US8212008B2 (no) |
EP (1) | EP2121760A2 (no) |
JP (1) | JP2010512791A (no) |
KR (1) | KR20090094846A (no) |
CN (1) | CN101679519A (no) |
AR (1) | AR064610A1 (no) |
AU (1) | AU2007338670A1 (no) |
BR (1) | BRPI0720841A2 (no) |
CA (1) | CA2673282A1 (no) |
IL (1) | IL199446A0 (no) |
MX (1) | MX2009006879A (no) |
NO (1) | NO20092743L (no) |
SG (1) | SG191442A1 (no) |
WO (1) | WO2008079352A2 (no) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101005124B1 (ko) * | 1999-05-13 | 2011-01-04 | 쉐링 코포레이션 | Ox2 수용체 동족체 |
EP2420515A4 (en) * | 2009-04-16 | 2013-08-28 | Univ Tokyo | DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-TMPRSS11E ANTIBODY |
EP2589609A1 (en) * | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
CN109369808B (zh) | 2012-08-24 | 2023-11-07 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
WO2015057906A1 (en) * | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Cd200 receptor 1 agonists |
MY194586A (en) | 2015-09-24 | 2022-12-05 | Daiichi Sankyo Co Ltd | Anti-garp antibody |
IL299099A (en) | 2016-06-27 | 2023-02-01 | Univ California | Combinations of cancer treatments |
TWI749367B (zh) * | 2018-09-14 | 2021-12-11 | 美商美國禮來大藥廠 | Cd200r促效劑抗體及其用途 |
JP2023502023A (ja) * | 2019-11-12 | 2023-01-20 | イーライ リリー アンド カンパニー | Cd200受容体アンタゴニスト結合分子 |
AU2021281417A1 (en) * | 2020-05-29 | 2022-12-08 | 23Andme, Inc. | Anti-CD200R1 antibodies and methods of use thereof |
WO2023196866A1 (en) * | 2022-04-06 | 2023-10-12 | Mirobio Limited | Engineered cd200r antibodies and uses thereof |
WO2023222068A1 (en) * | 2022-05-19 | 2023-11-23 | Harbour Biomed (Shanghai) Co., Ltd. | Anti-cd200r1 antibodies |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
KR101005124B1 (ko) * | 1999-05-13 | 2011-01-04 | 쉐링 코포레이션 | Ox2 수용체 동족체 |
DK1482973T3 (da) * | 2002-03-15 | 2009-12-07 | Schering Corp | Fremgangsmåde til modulering af CD200-receptorer |
US20060234226A1 (en) * | 2002-04-26 | 2006-10-19 | Fahner Robert L | Non-affinity purification of proteins |
PE20050925A1 (es) | 2003-11-10 | 2005-11-29 | Schering Corp | Anticuerpo recombinante humanizado anti-interleuquina 10 |
-
2007
- 2007-12-20 SG SG2011094760A patent/SG191442A1/en unknown
- 2007-12-20 EP EP07867958A patent/EP2121760A2/en not_active Withdrawn
- 2007-12-20 BR BRPI0720841-3A2A patent/BRPI0720841A2/pt not_active Application Discontinuation
- 2007-12-20 US US12/520,033 patent/US8212008B2/en not_active Expired - Fee Related
- 2007-12-20 JP JP2009542944A patent/JP2010512791A/ja active Pending
- 2007-12-20 WO PCT/US2007/026202 patent/WO2008079352A2/en active Application Filing
- 2007-12-20 AU AU2007338670A patent/AU2007338670A1/en not_active Abandoned
- 2007-12-20 MX MX2009006879A patent/MX2009006879A/es not_active Application Discontinuation
- 2007-12-20 AR ARP070105775A patent/AR064610A1/es unknown
- 2007-12-20 CN CN200780051592A patent/CN101679519A/zh active Pending
- 2007-12-20 KR KR1020097015014A patent/KR20090094846A/ko not_active Application Discontinuation
- 2007-12-20 CA CA002673282A patent/CA2673282A1/en not_active Abandoned
-
2009
- 2009-06-18 IL IL199446A patent/IL199446A0/en unknown
- 2009-07-21 NO NO20092743A patent/NO20092743L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2007338670A1 (en) | 2008-07-03 |
WO2008079352A3 (en) | 2009-03-19 |
JP2010512791A (ja) | 2010-04-30 |
CN101679519A (zh) | 2010-03-24 |
US8212008B2 (en) | 2012-07-03 |
AU2007338670A2 (en) | 2009-10-01 |
WO2008079352A2 (en) | 2008-07-03 |
AR064610A1 (es) | 2009-04-15 |
MX2009006879A (es) | 2009-07-03 |
BRPI0720841A2 (pt) | 2014-03-04 |
CA2673282A1 (en) | 2008-07-03 |
SG191442A1 (en) | 2013-07-31 |
EP2121760A2 (en) | 2009-11-25 |
KR20090094846A (ko) | 2009-09-08 |
US20100178296A1 (en) | 2010-07-15 |
IL199446A0 (en) | 2010-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20092743L (no) | Antistoffer mot CD200R | |
IL281876A (en) | Human antibodies that bind lymphocyte activating gene-3 (LAG-3) and their uses | |
NO20092652L (no) | Konstruert anti-TSLP-antistoff | |
IN2012DN00863A (no) | ||
PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
MA32982B1 (fr) | Proteines de liaison au recepteur cgrp humain | |
LTC2068874I2 (lt) | Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai | |
MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
NO20083492L (no) | 11-Beta HSD1 inhibitorer | |
ME00261B (me) | Tweak vezujuća antitijela | |
CY1117942T1 (el) | Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april) | |
EA201000844A1 (ru) | Связывающие wise агенты и эпитопы | |
NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
BRPI0817250A2 (pt) | Anticorpo anti-receptor da il-6. | |
CR20120210A (es) | Proteínas de enlace al antigeno il-23 humanas | |
MX2010008688A (es) | Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria. | |
DK2215119T3 (da) | Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme. | |
GB2437009A (en) | Ranking system | |
MY177564A (en) | Anti-nr10 antibody and use thereof | |
EA201000717A1 (ru) | Молекулы и способы, предназначенные для модуляции компонента системы комплемента | |
EA201270662A1 (ru) | Связывающие элементы для человеческого цитамегаловируса | |
BRPI0818865A2 (pt) | Anticorpos monoclonais contra proteína c ativada. | |
NO20083593L (no) | Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse | |
BRPI0814645A2 (pt) | Métodos e composições para tratar de doença autoimune. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |